Bisphosphonate Actions on Cancer

Calcified Tissue International

Volumn 73, Issue 4, 2003, Pages 315-318

  Yoneda, T ^a   Hashimoto, N ^a   Hiraga, T ^a  

^a NONE

Author keywords

Bisphosphonates; Cancer cells

Indexed keywords

ALENDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DOXORUBICIN; ETIDRONIC ACID; IBANDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL GROWTH; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GROWTH INHIBITION; HUMAN; MULTIPLE MYELOMA; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; REVIEW; VISCERAL METASTASIS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; HUMANS; NEOPLASMS;

EID: 0242578080     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-002-0025-x     Document Type: Review

References (29)

1. Van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Lowik C, Papapoulos S (1996) Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98:698-705
2. Boisser S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, Clezardin P (1997) Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 57:3890-3894
3. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse JM, Clezardin P (2000) Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60:2949-2954
4. Shipman CM, Croucher PI, Russell RGG, Helfrich MH, Rogers MJ (1999) The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 58:5294-5297
5. Fromigue O, Lagneaux L, Body JJ (2000) Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 45:2211-2221
6. Lee MV, Fong EM, Singer FR, Guenette RS (2001) Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61:2602-2608
7. Diet IJ, Solomayer E-F, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G (1998) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339:357-363
8. Saarto T, Blomqvist C, Virkkunen P, Elomaa II (2001) Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 19:10-17
9. Powles T, Paterson S, Kanis JA, et al. (2002) Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20:3219-3224
10. Coleman RE, Rubens RD (1987) The clinical course of bone metastases from breast cancer. Br J Cancer 55:61-66
11. Fleisch H, Reszka A, Rodan G, Rogers M, Bilezikian JP, Raisz LG, Rodan GA (2001) Mechanism of action. Principles of bone biology. Academic Press, San Diego, pp 1361-1385
12. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC (2000) Cellular and molecular mechanism of action of bisphosphonates. Cancer 88:2961-2978
13. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335:1785-1791
14. Body JJ, Bartl R, Burckhardt P, et al. (1998) Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 16:3890-3899
15. Mundy GR, Yoneda T (1998) Bisphosphonates as anticancer drugs. N Engl J Med 339:398-400
16. Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, Biermann JS (2002) American Society of Clinical Oncology Bisphosphonates Expert Panel American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 20:3719-3736
17. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T (1995) Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55:3551-3557
18. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF (1995) Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10:1478-1487
19. Hiraga T, Williams PJ, Mundy GR, Yoneda T (2201) The bisphosphonate ibandronate promotes apoptosis in MDA-231 human breast cancer cells in bone metastases. Cancer Res 61:4418-4424
20. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA (1991) Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88:2095-2105
21. Diel IJ, Solomayer E-F, Gollan C, Shutz F, Bastert G (2000) Bisphosphonates in the reduction of metastases in breast cancer: results of the extended follow-up of the first study population (abstract 314). Proceedings ASCO
22. Kostenuik PJ, Orr FW, Suyama K, Orr FW (1993) Increased growth rate and tumor burden of spontaneously metastatic Walker 256 cancer cells in the skeleton of bisphosphonate-treated rats. Cancer Res 53:5452-5457
23. Stearns ME, Wang M (1996) Effects of alendronate and taxol on PC-3ML cell bone metastases in SCID mice. Invasion Metastasis 16:116-131
24. Michigami T, Hiraga T, Williams PJ, Nishimura R, Mundy GR, Yoneda T (2002) The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res Treat 75:249-258
25. Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T (2000) Action of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 88:2979-2988
26. Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, Yee G, Biermann JS, Chlebowski RT, Pfister DG (2000) American society of clinical oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol 18:1378-1391
27. Sawada K, Morishige K, Tahara M, Kawagishi R, Ikebuchi Y, Tasaka K, Murata Y (2002) Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of Rho. Cancer Res 62:6015-6020
28. Green JR, Muller K, Jaeggi KA (1994) Preclinical pharmacology of CGP 42,446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9:745-751
29. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clezardin P (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538-6544